Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of ABI-H2158 in Healthy Adults
NCT04083716Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of firzacorvir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Assembly Biosciences, Inc. Primary endpoints: Area under the plasma concentration time curve at 120 hours and Maximum observed plasma concentration at 120 hours. Started Sep 2019; status: completed.
02
Drugs
firzacorvir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04083716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083716.